A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD | MicrobiomeTrials← Back to trialsNCT05281328
A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD
RecruitingPHASE2, PHASE3INTERVENTIONAL
Trial Details
Start: 2022-06-28Est. Completion: 2025-02-05
Enrollment target: 71 participants Locations- Mayo Clinic, Rochester, Minnesota, United States
- Mount Sinai Hospital, New York, New York, United States
- The New York Presbyterian Hospital, New York, New York, United States
- Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
- Bon Secours Richmond Community Hospital, Richmond, Virginia, United States
- University Hospitals KU Leuven, Leuven, Belgium
- Hannover Medical School, Hanover, Germany
- Universitätsklinikum Leipzig, Leipzig, Germany
- Universitaetsklinikum Müenster, Münster, Germany
- Radboud UMC, Department of Gastroenterology and Hepatology, Nijmegen, Netherlands
Other microbiome trials you might be interested in
Polycystic Ovary Syndrome
Background:
Brown adipose tissue (BAT) is a type of fat in the body. It may prevent weight gain, improve insulin sensit…
Bethesda, United StatesEst. completion Sep 30, 2026
NAFLDPCOS
Nonalcoholic steatohepatitis (NASH), or fat-related liver inflammation and scarring is projected to be the leading cause…
San Francisco, United StatesEst. completion Aug 2028